All companies
Perrigo logo

What smart money is saying about PerrigoIreland flag

PRGO · Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $1.91B

2 funds in our archive have pitched Perrigo — most recently Aristotle Small Mid Cap Equity in June 2025.

Company profile

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Fund coverage · 2 theses

  • Aristotle Small Mid Cap Equity
    June 2025

    Perrigo is a consumer health company undergoing a turnaround with new management's self-help initiatives aimed at improving profitability and driving above-average earnings growth.

    Read the full thesis
  • White Falcon Capital Management
    December 2024

    Perrigo is poised for significant growth with the launch of Opill, the first FDA-approved over-the-counter contraception, expected to contribute positively to earnings by 2025-26, potentially doubling its share price to $50.

    Read the full thesis

Read every full thesis on Perrigo

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans